Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment

ABSTRACT Chimeric antigen receptor (CAR) is a recombinant immunoreceptor combining an antibody-derived targeting fragment with signaling domains capable of activating cells, which endows T cells with the ability to recognize tumor-associated surface antigens independent of the expression of major hi...

Full description

Bibliographic Details
Main Authors: Zhenguang Wang, Yelei Guo, Weidong Han
Format: Article
Language:English
Published: Oxford University Press 2017-05-01
Series:Protein & Cell
Subjects:
chimeric antigen receptor
CAR-T
engineered T cells
adoptive cell therapy
cancer treatment
Online Access:http://link.springer.com/article/10.1007/s13238-017-0400-z

Internet

http://link.springer.com/article/10.1007/s13238-017-0400-z

Similar Items